News

Situated in the Company’s 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development pipeline for the Company’s growing Contract Development

The agreement will support research directed by Dr. Kamel Khalili, aimed to explore anti-viral activity of Piclidenoson on Coronaviruses viral load in a mammalian cell model system as

The later stage trial has been evaluating avelumab plus chemoradiotherapy (CRT) in comparison to standard-of-care CRT in patients having untreated locally advanced squamous cell carcinoma of the head

The Phase 1/2 trial represents the first study of an expanding phage library under FDA allowance for a multi-site study of intravenous administration and/or bladder instillation of phage

The advancement of ART24 into the Phase 1 clinical trial was based on its favorable profile exhibited in pre-clinical safety testing, as well as its demonstration of potent

The designation will help investigate the efficacy of Jardiance to minimise the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease. Jardiance, a

Forty Seven and Rocket Pharmaceuticals have entered into a research collaboration for evaluating a new treatment regimen in Fanconi Anemia, a rare paediatric disease. Fanconi Anemia affects the

U.S. Venture Partners (“USVP”) led the round, with participation from new investors including Nextech Invest Ltd., Hunt Investment Group, Pontifax Venture Capital, Colt Ventures LP and NS Investment.

Brii Bio’s funding to Columbia comes in the form of an unrestricted grant to facilitate creating a framework for the formation of strategic collaborations in areas of complementary